相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions
Gunnar Larfors et al.
BLOOD (2022)
Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics
Shiyu He et al.
FRONTIERS IN PHARMACOLOGY (2021)
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients
Philippe Rousselot et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Narrow Therapeutic Index drugs: clinical pharmacology perspective
Sam Habet
JOURNAL OF PHARMACY AND PHARMACOLOGY (2021)
The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer
Manvi Sharma et al.
CANCER (2019)
Tyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options
Roelof W. F. van Leeuwen et al.
CLINICAL PHARMACOKINETICS (2017)
Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
Yoji Ishida et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non-Small-Cell Lung Cancer
Michael P. Chu et al.
CLINICAL LUNG CANCER (2015)
The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria
Marc R. Yago et al.
AAPS JOURNAL (2014)
pH-Dependent Drug-Drug Interactions for Weak Base Drugs: Potential Implications for New Drug Development
L. Zhang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Prevalence of Acid-Reducing Agents (ARA) in Cancer Populations and ARA Drug-Drug Interaction Potential for Molecular Targeted Agents in Clinical Development
Gillian S. Smelick et al.
MOLECULAR PHARMACEUTICS (2013)
A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism
N. G. Hunfeld et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?
N. R. Budha et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects
Timothy Eley et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
A strategy for preclinical formulation development using GastroPlus (TM) as pharmacokinetic simulation tool and a statistical screening design applied to a dog study
M Kuentz et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2006)
The high solubility definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs
M Yazdanian et al.
PHARMACEUTICAL RESEARCH (2004)
Biowaivers for oral immediate-release products
F Faassen et al.
CLINICAL PHARMACOKINETICS (2004)
分享论文
